Diagnostic and prognostic significance of serum interleukins in Epileptic Encephalopathy with Spike Wave Activation in Sleep (EE-SWAS) syndrome

2024-9-1

Editorial Board

2024-9-1

Impact of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Paediatric Acquired Demyelinating Disease: Intellectual Functioning and Academic Performance

2024-9-1

Tocilizumab in acute necrotizing encephalopathy (ANE): How much, how soon, and will it improve outcomes beyond survival?

2024-9-1

Standardizing Qualitative Assessments of Developing Myelination on Brain MRI

2024-9-1

Acute necrotizing encephalopathy infected with the SARS-CoV-2 in children: case series and literature review of clinical outcomes with the use of Tocilizumab

2024-9-1

Long term outcome in non-multiple sclerosis paediatric acquired demyelinating syndromes

2024-9-1

Age-appropriate or delayed myelination? Scoring myelination in routine clinical MRI

2024-9-1

Effects of cycling training on balance and gait in children with Duchenne muscular dystrophy: A randomized controlled study

2024-9-1

Consequences of Vestibular Hypofunction in Children with ADHD/DCD

2024-9-1

Health-related quality of life in 153 children with neuromuscular disorders in Latin America: is it age, functional dependance or diagnosis?

2024-9-1

Perspectives of cerebral palsy experts on access to health care in Europe

2024-9-1

The importance of long term follow-up in children with acquired demyelinating syndromes

2024-9-1

Exploring the correlation between paediatric narcolepsy and serum neurofilament light chain levels: An exploratory study

2024-8-20

Cognitive and emotional-behavioural outcomes of Turkish Duchenne muscular dystrophy population and its association with motor function

2024-8-18

Understanding the scale of the problem: how to standardise the measurement of Childhood Movement Disorders?

2024-8-1

Outcomes for Patients in the RESTORE Registry with Spinal Muscular Atrophy and Four or More SMN2 Gene Copies Treated with Onasemnogene Abeparvovec

2024-8-1

Understanding the scale of the problem: how to standardise the measurement of Childhood Movement Disorders?

2024-8-1

CSF-profile and hypocretin levels in children with narcolepsy type 1 and 2

2024-8-1

Management, treatment, and clinical approach of Sydenham's Chorea in Children: Italian Survey on Expert-Based Experience

2024-8-1

Early motor, cognitive, language, behavioural and social emotional development in infants and young boys with Duchenne Muscular Dystrophy- a systematic review

2024-7-6

Testing for MOG-IgG in CSF: relevant or not?

2024-7-1

Reliability and validity of a newly developed PANDAS/PANS questionnaire

2024-7-1

Editorial Board

2024-7-1

Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life

2024-7-1

Frequency and clinical relevance of MOG-antibodies in CSF in pediatric patients with MOG antibody-associated diseases

2024-7-1

Insights from European Reference Network for Rare Neurological Disorders Study surveys on Diagnosis, Treatment, and Management of NKX2-1-Related Disorders

2024-7-1

Distinct attentional and executive profiles in Neurofibromatosis type 1: is there difference with primary attention deficit-hyperactivity disorder?

2024-7-1

Gene therapy offers promise, but timing is crucial for SMA treatment.

2024-7-1

What you see is what you get? Eye gaze as a window to vocabulary in Rett Syndrome

2024-7-1

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies

2024-7-1

Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

2024-7-1

The When, Why, and How of Using Glycopyrronium to Diminish Drooling in Children with Neurodevelopmental Disabilities: Implications for Clinical Practice

2024-7-1

Cognitive, adaptive and perseverative aspects characterization of children with XLMTM: an explorative study

2024-7-1

GLUT1DS focus on dysarthria

2024-7-1

Characterising the typical range of influenza-associated neurological symptoms in children

2024-7-1

Corrigendum to “Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy” [Eur. J. Paediatr. Neurol. 47 (2023) 25-34]

2024-7-1

Longitudinal semi-quantitative MRI values in CP-children under 3 years of age

2024-7-1

Current approach to Cerebral Palsy

2024-7-1

2024 update: European consensus statement on gene therapy for spinal muscular atrophy

2024-7-1

Motor Imagery Ability of Children with Duchenne Muscular Dystrophy: Reliability and Validity of Kinesthetic and Visual Imagery Questionnaire-10, and Its Association with Cognitive Status

2024-7-1

Assessment of Somatosensory Profiles by Quantitative Sensory Testing in Children and Adolescents with and without Cerebral Palsy and Chronic Pain

2024-7-1

The role of fidgety movements and early motor repertoire in predicting mobility outcomes in infants with myelomeningocele

2024-7-1

In memoriam: Jaap Valk, 1929–2024

2024-7-1

Improving paediatric movement disorders care: Insights on rating scales utilization and clinical practice

2024-6-29

The effect of live music therapy on white matter microstructure in very preterm infants – a randomized controlled trial

2024-6-22

Validation of the Internet Addiction Test for Adolescents (IAT-A) in the Georgian language

2024-6-19

Diagnostic accuracy is required when analysing cohorts with mitochondrial disorders

2024-6-6

Response to the Letter by Josef Finsterer, MD, PhD.

2024-6-1

Neurological involvement related to the influenza virus in children: A 5-year single-centre retrospective study

2024-5-28